ArticleFrontiers in immunology2025
Computational design and evaluation of multiepitope vaccines against herpes simplex virus type 1.
Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Integrative immunoinformatics and molecular modeling approaches for the rational design and in silico validation of a multi-epitope vaccine candidate against human herpesvirus 7.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- From Yufeining to Kaempferol: Multi-Target Anti-Inflammatory, Antioxidant, and Anti-Apoptotic Mechanisms Targeting the STAT3-TP53-IL1B Signaling Network in COPD Therapy.Molecules (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Herpes simplex virus type 1 (HSV-1) is a prevalent human pathogen, causing infections in various tissues and leading to severe complications such as herpes simplex encephalitis and cognitive impairments. Despite existing antiviral treatments, recurrent infections and the lack of effective vaccines highlight the need for new preventive measures. Methods: We employed immunogenomic and bioinformatics methods to design two multi-epitope vaccine constructs 1 and 2 against HSV-1. The Immune Epitope Database was used to identify B-cell and T-cell epitopes from HSV-1 glycoproteins. The IFN epitope server and the IL4pred/IL-10pred server were used to ascertain the activation possibility of IFN-γ, IL-4, and IL-10. The NetMHC-4.0 and NetMHCII2.3 servers were used to identify MHC epitopes. The constructed vaccine was analyzed for antigenicity and allergenicity using the VaxiJen v2.0 and AllergenFP servers. The three-dimensional structure of the vaccine construct was constructed using the AlphaFold3 tool. The ClusPro 2.0 server was utilized for molecular docking and the Desmond module in Schrodinger 2021-1 was utilized for molecular dynamics and MM/PBSA analysis. The immunogenicity and the corresponding immune response curves were analyzed using the C-ImmSim server. Results: Bioinformatics analysis demonstrated that these vaccines exhibited both good affinity and immunogenicity, and were non-toxic and non-allergenic to the host. In addition, vaccine construct 2 exhibits superior stability and binding affinity with TLR9, and is more effective in triggering a robust immune response. Discussion: This approach targets the key mechanisms of HSV-1 entry and TLR-mediated immune responses, providing a potential strategy for preventing and treating HSV-1 infections. Furthermore, the identified and optimized vaccine construct offers a promising avenue for developing a preventive vaccine against HSV-1, addressing the critical need for better control of this widespread virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.